elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q26864906-8E9A547C-C6F7-4722-A6E5-4CCF5AC840CB
Q26864906-8E9A547C-C6F7-4722-A6E5-4CCF5AC840CB
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26864906-8E9A547C-C6F7-4722-A6E5-4CCF5AC840CB
Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data
P2860
Q26864906-8E9A547C-C6F7-4722-A6E5-4CCF5AC840CB
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26864906-8E9A547C-C6F7-4722-A6E5-4CCF5AC840CB
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
5586366e4cef4a10df9260cd3c9e774458a9e6c6
P2860
Risks and benefits of infliximab for the treatment of Crohn's disease